GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » Cash Ratio

Sio Gene Therapies (Sio Gene Therapies) Cash Ratio

: 21.43 (As of Dec. 2022)
View and export this data going back to 2015. Start your Free Trial

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Sio Gene Therapies's Cash Ratio for the quarter that ended in Dec. 2022 was 21.43.

Sio Gene Therapies has a Cash Ratio of 21.43. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Sio Gene Therapies's Cash Ratio or its related term are showing as below:

SIOX's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.97
* Ranked among companies with meaningful Cash Ratio only.

Sio Gene Therapies Cash Ratio Historical Data

The historical data trend for Sio Gene Therapies's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Cash Ratio
Premium Member Only Premium Member Only Premium Member Only 3.31 2.46 2.52 10.97 4.90

Sio Gene Therapies Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cash Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.41 4.90 5.99 10.32 21.43

Competitive Comparison

For the Biotechnology subindustry, Sio Gene Therapies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sio Gene Therapies Cash Ratio Distribution

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's Cash Ratio falls into.



Sio Gene Therapies Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Sio Gene Therapies's Cash Ratio for the fiscal year that ended in Mar. 2022 is calculated as:

Cash Ratio (A: Mar. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=63.729/13.002
=4.90

Sio Gene Therapies's Cash Ratio for the quarter that ended in Dec. 2022 is calculated as:

Cash Ratio (Q: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=46.127/2.152
=21.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sio Gene Therapies  (OTCPK:SIOX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Sio Gene Therapies Cash Ratio Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sio Gene Therapies (Sio Gene Therapies) Business Description

Traded in Other Exchanges
N/A
Address
130 West 42nd Street, 26th Floor, New York, NY, USA, 10036
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.
Executives
Parag V Meswani officer: Chief Commercial Officer 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu officer: Chief Executive Officer C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif officer: Principal Financial Officer C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo 10 percent owner C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado 10 percent owner 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901

Sio Gene Therapies (Sio Gene Therapies) Headlines

From GuruFocus

Sio Gene Therapies Announces Reorganization of R&D Group

By Marketwired Marketwired 10-21-2021

Sio Gene Therapies to Participate in Upcoming Conferences

By Marketwired Marketwired 09-23-2021

Sio Gene Therapies Provides Corporate Update

By GuruFocusNews GuruFocusNews 04-27-2022

Sio Gene Therapies Inc (SIOX) CEO Pavan Cheruvu Bought $248,000 of Shares

By GuruFocus Research GuruFocus Editor 03-25-2021